论文部分内容阅读
目的联合检测ER、PR、抑癌基因p53和癌基因C-erbB-2在乳腺浸润性导管癌中的表达情况,来探讨与浸润性导管癌淋巴结转移及预后之间的联系。方法采用免疫组化S-P法分别检测242例乳腺浸润性导管癌ER、PR、C-erbB-2和p53的表达。结果242例乳腺浸润性导管癌中ER、PR、C-erbB-2和p53的阳性表达率分别为69.42%,63.22%,46.28%,34.30%。ER、PR基因表达与有无淋巴结转移及病理组织学分级有关;C-erbB-2、p53阳性表达率与有无淋巴结转移及病理组织学分级有关(p<0.05),C-erbB-2、p53共同阳性表达与淋巴结转移有关。结论联合检测乳腺浸润性导管癌ER、PR、C-erbB-2和p53基因表达对预测乳腺浸润性导管癌淋巴结转移及判断预后有重要意义。
Objective To detect the expression of ER, PR, tumor suppressor gene p53 and oncogene C-erbB-2 in invasive ductal carcinoma of the breast (IDC) to explore the relationship between lymph node metastasis and prognosis of invasive ductal carcinoma. Methods The expressions of ER, PR, C-erbB-2 and p53 were detected by immunohistochemical S-P method in 242 cases of invasive ductal carcinoma of the breast. Results The positive rates of ER, PR, C-erbB-2 and p53 in 242 cases of breast invasive ductal carcinoma were 69.42%, 63.22%, 46.28% and 34.30% respectively. The expression of C-erbB-2 and p53 was correlated with lymph node metastasis and histopathological grade (p <0.05). The expression of C-erbB-2 and p53 was positively correlated with the expression of C-erbB- p53 common positive expression and lymph node metastasis. Conclusions Combined detection of ER, PR, C-erbB-2 and p53 gene expression in invasive ductal carcinoma of breast is important for predicting lymph node metastasis and prognosis in invasive ductal carcinoma of the breast.